Icapamespib（PU-HZ151；PU-AD）是口服有效、具慢解离动力学的选择性Epichaperomes（HSP90组装病理伴侣复合物）抑制剂，可穿透血脑屏障，通过非共价结合HSP90诱导Epichaperomes解体，恢复正常蛋白-蛋白相互作用网络，同时破坏疾病相关异常蛋白互作网络，减少神经毒性蛋白聚集和肿瘤细胞存活信号，适用于阿尔茨海默病等神经退行性疾病及胶质母细胞瘤、转移性乳腺癌等研究。

[1] Bolaender A, Zatorska D, He H, Joshi S, Sharma S, Digwal CS, Patel HJ, Sun W, Imber BS, Ochiana SO, Patel MR, Shrestha L, Shah SK, Wang S, Karimov R, Tao H, Patel PD, Martin AR, Yan P, Panchal P, Almodovar J, Corben A, Rimner A, Ginsberg SD, Lyashchenko S, Burnazi E, Ku A, Kalidindi T, Lee SG, Grkovski M, Beattie BJ, Zanzonico P, Lewis JS, Larson S, Rodina A, Pillarsetty N, Tabar V, Dunphy MP, Taldone T, Shimizu F, Chiosis G. Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system. Nat Commun. 2021 Aug 3;12(1):4669. doi: 10.1038/s41467-021-24821-2. PMID: 34344873; PMCID: PMC8333062.[2]Pasala C, Digwal CS, Sharma S, Wang S, Bubula A, Chiosis G. Epichaperomes: redefining chaperone biology and therapeutic strategies in complex diseases. RSC Chem Biol. 2025 Mar 19;6(5):678-698. doi: 10.1039/d5cb00010f. PMID: 40144950; PMCID: PMC11933791.